Arterial and Venous Pharmacokinetics of Morphine-6-Glucuronide and Impact of Sample Site on Pharmacodynamic Parameter Estimates

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Anesthesia and Analgesia

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1213/ANE.0b013e3181e5e8afPMID 20547824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic-Pharmacodynamic Modeling of Morphine-6-glucuronide-induced Analgesia in Healthy Volunteers: Absence of Sex Differences

  2004cited by this paper
• Pharmacodynamic Effect of Morphine-6-glucuronide versus Morphine on Hypoxic and Hypercapnic Breathing in Healthy Volunteers

  2003cited by this paper
• Mechanisms of Direct Inhibitory Action of Propofol on Uterine Smooth Muscle Contraction in Pregnant Rats

  2001cited by this paper
• Sex Differences in Morphine Analgesia: An Experimental Study in Healthy Volunteers

  2000cited by this paper
• Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam.

  1998influential reference
• The Impact of Arteriovenous Concentration Differences on Pharmacodynamic Parameter Estimates

  1997influential reference
• Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.

  1994influential reference

• Clinical Pharmacokinetics and Pharmacodynamics of Naloxone

  2024cites this paper
• Critical view of the effect site modelling of propofol

  2019cites this paper
• Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling

  2019cites this paper
• Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers

  2019cites this paper
• Critical view of the effect site modelling of propofol.

  2019cites this paper
• Sampling site has a critical impact on PBPK modeling

  2019cites this paper
• Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(–) Ketamine Concentrations

  2018cites this paper
• Pharmacokinetic–Pharmacodynamic Modelling of Anesthetic Drugs

  2017cites this paper
• Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers

  2017cites this paper
• Pharmacokinetic and pharmacodynamic analysis in anesthesia : a modeling odyssey

  2017cites this paper
• Arterial Line Placement: Safety First.

  2016cites this paper
• The haemodynamic and pharmacologic interaction of medetomidine and peripheral antagonist MK-467 and their dose-dependency in dogs

  2016cites this paper
• Quantitative Aspects of Nanodelivery Across the Blood-Brain Barrier Exemplified with the Opioid Peptide

  2015cites this paper
• Quantitative Aspects of Nanodelivery Across the Blood-Brain Barrier : Exemplified with the Opioid Peptide DAMGO

  2015cites this paper
• Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site

  2015cites this paper
• Reversal of opioid‐induced respiratory depression by BK‐channel blocker GAL021: A pharmacokinetic‐pharmacodynamic modeling study in healthy volunteers

  2015cites this paper
• Postoperative Pain Management in Cardiac Surgery

  2014cites this paper
• Recirculatory pharmacokinetic modeling: what goes around, comes around.

  2012cites this paper
• Opioid Modeling of Central Respiratory Drive Must Take Upper Airway Obstruction into Account

  2011cites this paper
• Multiples of Minimal Alveolar Concentration of Volatile Agents Are Not Necessarily Equipotent

  2011cites this paper
• Multiples of minimal alveolar concentration of volatile agents are not necessarily equipotent.

  2011cites this paper